A randomized double-blind study of carbamazepine in the treatment of cocaine abuse
A randomized double-blind study of carbamazepine in the treatment of cocaine abuse
复制标题
DOI：
10.1016/s0009-9236(97)90155-7
复制
发表时间：
1997-07-01
影响因子：
6.7
通讯作者：
Graves, NM
中科院分区：
文献类型：
--
作者：
Halikas, JA;Crosby, RD;Graves, NM
进行了12周、随机、双盲、安慰剂对照、固定剂量的卡马西平（400 mg和800 mg）治疗可卡因依赖的门诊研究。分析了治疗条件和卡马西平血清水平的数据。结果变量包括受试者保留、可卡因尿分析、自我报告的可卡因使用、可卡因渴望、患者和临床总体印象、可卡因药物损害评定量表和副作用。与安慰剂相比，400 mg治疗条件在研究过程中表现出可卡因尿分析阳性率的更大降低以及渴望强度和持续时间的降低。较高的血清卡马西平水平与较低的阳性率可卡因尿分析，更少的天自我报告的可卡因使用，短暂的渴望发作，更大的主题间隔保留。这些研究结果和研究设计的临床和方法学意义进行了讨论。
12-week, randomized, double-blind, placebo-controlled, fixed-dose outpatient study of carbamazepine (400 mg and 800 mg) in the treatment of cocaine dependence was performed. Data were analyzed with respect to both treatment condition and carbamazepine serum levels. Outcome variables included subject retention, cocaine urinalysis, self-reported cocaine use, cocaine craving, patient and clinical global impressions, the Drug Impairment Rating Scale for Cocaine, and side effects. Compared with placebo, the 400 mg treatment condition exhibited a greater decrease in the rate of positive cocaine urinalyses and a reduction in intensity and duration of craving over the course of the study. Higher serum carbamazepine levels were associated with a lower rate of positive cocaine urinalysis, fewer days of self-reported cocaine use, briefer craving episodes, and greater subject interval retention. The clinical and methodologic implications of these findings and of the study design are discussed.